CARM1 and plasma cell myeloma: H3R17me2 is associated with transcriptional activation based on the recruitment of polymerase-associated factor 1 complex to initiate transcription in humans (89, 118), supported by the antiproliferative effects of a specific CARM1 inhibitor on multiple myeloma cell lines (119, 120).